FDA OKs Amneal’s generic Lidoderm Patch

The FDA approves Amneal Pharmaceuticals’ (AMRX +1.1%) marketing application for its generic version of Endo Pharmaceuticals’ (ENDP -1.2%) Lidoderm Patch, 5% for the treatment of post-herpetic neuralgia.

Per IQVIA, the U.S. market is ~$282M.

https://seekingalpha.com/news/3608586-fda-oks-amneals-generic-lidoderm-patch